CSBR
NASDAQ · Life Sciences Tools & Services
Champions Oncology Inc
$6.16
-0.27 (-4.20%)
Financial Highlights (FY 2026)
Revenue
55.25M
Net Income
4.56M
Gross Margin
50.1%
Profit Margin
8.3%
Rev Growth
+5.1%
D/E Ratio
0.06
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 50.1% | 50.1% | 61.8% | 61.8% |
| Operating Margin | 8.0% | 7.2% | 20.5% | 17.5% |
| Profit Margin | 8.3% | 7.9% | 14.6% | 15.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 55.25M | 52.59M | 19.71M | 19.48M |
| Gross Profit | 27.71M | 26.37M | 12.17M | 12.03M |
| Operating Income | 4.42M | 3.79M | 4.04M | 3.42M |
| Net Income | 4.56M | 3.91M | 2.89M | 3.05M |
| Gross Margin | 50.1% | 50.1% | 61.8% | 61.8% |
| Operating Margin | 8.0% | 7.2% | 20.5% | 17.5% |
| Profit Margin | 8.3% | 7.9% | 14.6% | 15.7% |
| Rev Growth | +5.1% | +5.1% | +2.4% | -6.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.34M | 2.34M | 33.95M | 38.63M |
| Total Equity | 40.15M | 40.15M | 59.74M | 52.97M |
| D/E Ratio | 0.06 | 0.06 | 0.57 | 0.73 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 6.01M | 5.43M | 6.10M | 5.64M |
| Free Cash Flow | — | — | 2.36M | 1.92M |